NHG-Richtlijnen
NHG-Behandelrichtlijn
1.1
oktober 2017
september 2024
P. Psychische problemen

Richtlijnen beleid

Naar Volledige tekst ›

Algemeen beleid

Naar Volledige tekst ›

Stoppen-met-rokenadvies

Naar Volledige tekst ›

Begeleiding bij stoppen met roken

Naar Volledige tekst ›

Niet-medicamenteuze behandeling (extra aanbod in huisartsenpraktijk)

Naar Volledige tekst ›

Medicamenteuze behandeling

Naar Volledige tekst ›

Stoppen met de e-sigaret

Naar Volledige tekst ›

Controles

Naar Volledige tekst ›

Consultatie en verwijzing

Naar Volledige tekst ›

Belangrijkste wijzigingen

Naar Samenvatting ›

Kernboodschappen

Naar Samenvatting ›

Inleiding

Naar Samenvatting ›

Scope

Naar Samenvatting ›

Buiten de scope

Naar Samenvatting ›

Samenwerking en afstemming

Naar Samenvatting ›

Achtergronden

Naar Samenvatting ›

Epidemiologie

Naar Samenvatting ›

Etiologie en pathofysiologie

Naar Samenvatting ›

Nicotineafhankelijkheid

Naar Samenvatting ›

Gevolgen van roken

Naar Samenvatting ›

Motivatie

Naar Samenvatting ›

Richtlijnen beleid

Naar Samenvatting ›

Algemeen beleid

Naar Samenvatting ›

Rookstatus in kaart brengen

Naar Samenvatting ›

Stoppen-met-rokenadvies

Naar Samenvatting ›

Kort stopadvies

Naar Samenvatting ›

Motivatieverhoging

Naar Samenvatting ›

Begeleiding bij het stoppen met roken

Naar Samenvatting ›

Algemene begeleiding

Naar Samenvatting ›

Praktische toepassing

Naar Samenvatting ›

Aanpassing van de dosering van gelijktijdig gebruikte geneesmiddelen

Naar Samenvatting ›

Thuisarts en keuzekaart

Naar Samenvatting ›

Niet-medicamenteuze behandeling (extra aanbod in huisartsenpraktijk)

Naar Samenvatting ›

Intensieve gedragsmatige ondersteuning

Naar Samenvatting ›

Niet-intensieve gedragsmatige ondersteuning

Naar Samenvatting ›

E-health (digitale zelfhulp) en digitale zorg

Naar Samenvatting ›

Minderen als opmaat naar stoppen met roken

Naar Samenvatting ›
Praktische toepassing
Naar Samenvatting ›

De e-sigaret als hulpmiddel bij stoppen met roken

Naar Samenvatting ›

Beweeg- en trainingsprogramma’s

Naar Samenvatting ›

Medicamenteuze behandeling

Naar Samenvatting ›

Voorkeursmiddelen

Naar Samenvatting ›

Praktische toepassing

Naar Samenvatting ›

Medicamenteus beleid bij zwangerschap

Naar Samenvatting ›
Nicotinevervangende middelen bij zwangeren
Naar Samenvatting ›
Praktische toepassing van nicotinevervangende middelen bij zwangeren
Naar Samenvatting ›

Nicotinevervangende middelen bij borstvoeding

Naar Samenvatting ›

Stoppen met de e-sigaret

Naar Samenvatting ›

Controles

Naar Samenvatting ›

Consultatie en verwijzing

Naar Samenvatting ›

Referenties

  1. Bartels-Velthuis AA, Visser E, Arends J, Pijnenborg GHM, Wunderink L, Jörg F, et al. Towards a comprehensive routine outcome monitoring program for people with psychotic disorders: The Pharmacotherapy Monitoring and Outcome Survey (PHAMOUS). Schizophr Res 2018;197:281-7.
  2. Troelstra S, Croes E, Bommelé J, Willemsen M, al e. Factsheet elektronische sigaretten. 2020.
  3. Hupkens C, Geuijen P, Hiemstra M. Aanvullende module leefstijlmonitor middelen. 2020.
  4. Van Westen-Lagerweij NA, Bommelé J, Willemsen MC, Croes EA. Mentioning smoking cessation assistance during healthcare consultations matters: findings from Dutch survey research. Eur J Public Health 2022;32:747-52.
  5. Bommelé J, Willemsen MC. Kerncijfers roken 2021. 2022.
  6. Bhatta DN, Glantz SA. Association of E-Cigarette Use With Respiratory Disease Among Adults: A Longitudinal Analysis. Am J Prev Med 2020;58:182-90.
  7. Parekh T, Pemmasani S, Desai R. Risk of Stroke With E-Cigarette and Combustible Cigarette Use in Young Adults. Am J Prev Med 2020;58:446-52.
  8. Goniewicz ML, Smith DM, Edwards KC, Blount BC, Caldwell KL, Feng J, et al. Comparison of Nicotine and Toxicant Exposure in Users of Electronic Cigarettes and Combustible Cigarettes. JAMA Netw Open 2018;1:e185937.
  9. Shahab L, Goniewicz ML, Blount BC, Brown J, McNeill A, Alwis KU, et al. Nicotine, Carcinogen, and Toxin Exposure in Long-Term E-Cigarette and Nicotine Replacement Therapy Users: A Cross-sectional Study. Ann Intern Med 2017;166:390-400.
  10. HBSC. Gezondheid en welzijn van jongeren in Nederland. 2021.
  11. Garritsen H, Bommelé J, De Nerée C, Troelstra S, Croes E, Willemsen M. Jongerenmonitor tabaks- en nicotineproducten. Het gebruik van tabaks- en nicotineproducten door jongeren en jongvolwassenen van 12 tot en met 25 jaar (herziene versie). 2023.
  12. Monshouwer K, Tuithof M, Van Dorsselaer S. Middelengebruik onder studenten van 16-18 jaar op het mbo en hbo. 2022.
  13. Eaton DL, Kwan LY, Stratton K. Public Health Consequences of E-Cigarettes. In: Eaton DL, Kwan LY, Stratton K, editors. Public Health Consequences of E-Cigarettes. Washington (DC): National Academies Press (US)
    Copyright 2018 by the National Academy of Sciences. All rights reserved.; 2018.
  14. Scheffer-van Schayck T, Thissen V, Errami F, Tuithof M. Monitor middelengebruik en zwangerschap 2021, middelengebruik van vrouwen en hun partners voor, tijdens en na de zwangerschap. Trimbos Instituut: Trimbos Instituut, Nederlands Institute of Menthal Health and Addiction; 2022. p. 1-24.
  15. Patientenfederatie Nederland. Rapport stoppen met roken. 2023.
  16. Knol K, Hilvering C, Wagener DJT, Willemsen MC. Tabaksgebruik: gevolgen en bestrijding (2005):[p. 283-99 pp.].
  17. Pidoplichko VI, DeBiasi M, Williams JT, Dani JA. Nicotine activates and desensitizes midbrain dopamine neurons. Nature 1997;390:401-4.
  18. Russell MAH. Nicotine intake and its control over smoking. In: Wonnacott S, Russell MAH, Stolerman IP, editors. Nicotine Psychopharmacology: Molecular, Cellular, and Behavioural Aspects: Oxford University Press; 1990. p. 0.
  19. Psychiatry.org. (2023). Geraadpleegd op 18 december 2023. Ga naar bron
  20. Fiore MC. Treating tobacco use and dependence: an introduction to the US Public Health Service Clinical Practice Guideline. Respir Care 2000;45:1196-9.
  21. Heatherton TF, Kozlowski LT, Frecker RC, Fagerström KO. The Fagerström Test for Nicotine Dependence: a revision of the Fagerström Tolerance Questionnaire. Br J Addict 1991;86:1119-27.
  22. Reep-van den Bergh CMM, Harteloh PPM, Croes EA. Doodsoorzaak nr. 1 bij jonge Nederlanders: de sigaret. Ned Tijdschr Geneeskd 2017;161:D1991.
  23. Stivoro. Roken: de harde feiten 2006 (2006). Ga naar bron
  24. Twardella D, Loew M, Rothenbacher D, Stegmaier C, Ziegler H, Brenner H. The diagnosis of a smoking-related disease is a prominent trigger for smoking cessation in a retrospective cohort study. J Clin Epidemiol 2006;59:82-9.
  25. Zhou W, Heist RS, Liu G, Park S, Neuberg DS, Asomaning K, et al. Smoking cessation before diagnosis and survival in early stage non-small cell lung cancer patients. Lung Cancer 2006;53:375-80.
  26. Stead LF, Buitrago D, Preciado N, Sanchez G, Hartmann-Boyce J, Lancaster T. Physician advice for smoking cessation. Cochrane Database Syst Rev 2013;2013:Cd000165.
  27. Jansen J, Heemstra I, Van Dijk K, De Leur M, Van 't K, Ricke E, al. e. Zorgstandaard tabaksverslaving 2022. NVAB: 2022.
  28. Lancaster T, Stead LF. Individual behavioural counselling for smoking cessation. Cochrane Database Syst Rev 2017;3:Cd001292.
  29. Stead LF, Carroll AJ, Lancaster T. Group behaviour therapy programmes for smoking cessation. Cochrane Database Syst Rev 2017;3:Cd001007.
  30. NHS. Cutting down before you quit smoking (2022). Ga naar bron
  31. Lindson N, Klemperer E, Hong B, Ordóñez-Mena JM, Aveyard P. Smoking reduction interventions for smoking cessation. Cochrane Database Syst Rev 2019;9:Cd013183.
  32. Hartmann-Boyce J, Lindson N, Butler AR, McRobbie H, Bullen C, Begh R, et al. Electronic cigarettes for smoking cessation. Cochrane Database Syst Rev 2022;11:Cd010216.
  33. Hajat C, Stein E, Shantikumar S, Niaura R, Ferrara P, Polosa R. A scoping review of studies on the health impact of electronic nicotine delivery systems. Intern Emerg Med 2022;17:241-68.
  34. Lucchiari C, Masiero M, Mazzocco K, Veronesi G, Maisonneuve P, Jemos C, et al. Nicotine-Free E-Cigarettes Might Promote Tobacco Smoking Reduction Better Than Nicotine Delivery Devices: Results of a Double-Blind Randomized Controlled Trial at 1 Year. Curr Oncol 2022;29:8579-90.
  35. Klonizakis M, Gumber A, McIntosh E, Brose LS. Medium- and longer-term cardiovascular effects of e-cigarettes in adults making a stop-smoking attempt: a randomized controlled trial. BMC Med 2022;20:276.
  36. Hajek P, Przulj D, Pesola F, Griffiths C, Walton R, McRobbie H, et al. Electronic cigarettes versus nicotine patches for smoking cessation in pregnancy: a randomized controlled trial. Nat Med 2022;28:958-64.
  37. Jones G, McIntosh E, Brose LS, Klonizakis M. Participant Experiences of a Quit Smoking Attempt Through Either Nicotine Replacement Therapy (NRT) Methods or the Use of an E-cigarette. J Addict Med 2022;16:272-7.
  38. Szukalska M, Szyfter K, Florek E, Rodrigo JP, Rinaldo A, Mäkitie AA, et al. Electronic Cigarettes and Head and Neck Cancer Risk-Current State of Art. Cancers (Basel) 2020;12.
  39. Levett JY, Filion KB, Reynier P, Prell C, Eisenberg MJ. Efficacy and Safety of E-Cigarette Use for Smoking Cessation: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Am J Med 2023;136:804-13.e4.
  40. Anandan AS, Leung J, Chan GCK, Sun T, Connor JP, Hall WD, Stjepanović D. Common adverse events of electronic cigarettes compared with traditional nicotine replacement therapies: A systematic review and meta-analysis. Drug Alcohol Rev 2023;42:1278-87.
  41. Rose JE, Frisbee S, Campbell D, Salley A, Claerhout S, Davis JM. Smoking reduction using electronic nicotine delivery systems in combination with nicotine skin patches. Psychopharmacology (Berl) 2023;240:1901-9.
  42. Przulj D, Pesola F, Smith KM, McRobbie H, Coleman T, Lewis S, et al. Helping pregnant smokers quit: a multicentre randomised controlled trial of electronic cigarettes versus nicotine replacement therapy. Health Technology Assessment 2023;27:1-53.
  43. Kaplan B, Galiatsatos P, Breland A, Eissenberg T, Cohen JE. Effectiveness of ENDS, NRT and medication for smoking cessation among cigarette-only users: A longitudinal analysis of PATH Study wave 3 (2015– 2016) and 4 (2016–2017), adult data. Tobacco Control: An International Journal 2023;32:302-7.
  44. West R, Hajek P, Stead L, Stapleton J. Outcome criteria in smoking cessation trials: proposal for a common standard. Addiction 2005;100:299-303.
  45. Visser WFea. De gezondheidsrisico's van e-sigaret gebruik. RIVM: 2014 2014. Report No.
  46. Hajek P, Phillips-Waller A, Przulj D, Pesola F, Myers Smith K, Bisal N, et al. A Randomized Trial of E-Cigarettes versus Nicotine-Replacement Therapy. N Engl J Med 2019;380:629-37.
  47. Hendlin YH. Alert: public health implications of electronic cigarette waste. Am J Public Health 2018;108:1489-90.
  48. Pourchez J, Mercier C, Forest V. From smoking to vaping: a new environmental threat? Lancet Respir Med 2022;10:e63-e4.
  49. Ussher MH, Taylor AH, Faulkner GE. Exercise interventions for smoking cessation. Cochrane Database Syst Rev 2014:Cd002295.
  50. Stead LF, Perera R, Bullen C, Mant D, Hartmann-Boyce J, Cahill K, Lancaster T. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev 2012;11:Cd000146.
  51. Hartmann-Boyce J, Chepkin SC, Ye W, Bullen C, Lancaster T. Nicotine replacement therapy versus control for smoking cessation. Cochrane Database Syst Rev 2018;5:Cd000146.
  52. Greenland S, Satterfield MH, Lanes SF. A meta-analysis to assess the incidence of adverse effects associated with the transdermal nicotine patch. Drug Saf 1998;18:297-308.
  53. Mills EJ, Wu P, Lockhart I, Wilson K, Ebbert JO. Adverse events associated with nicotine replacement therapy (NRT) for smoking cessation. A systematic review and meta-analysis of one hundred and twenty studies involving 177,390 individuals. Tob Induc Dis 2010;8:8.
  54. Hughes JR, Stead LF, Hartmann-Boyce J, Cahill K, Lancaster T. Antidepressants for smoking cessation. Cochrane Database Syst Rev 2014;2014:Cd000031.
  55. Livingstone-Banks J, Fanshawe TR, Thomas KH, Theodoulou A, Hajizadeh A, Hartman L, Lindson N. Nicotine receptor partial agonists for smoking cessation. Cochrane Database of Systematic Reviews 2023.
  56. Cahill K, Stead LF, Lancaster T. Nicotine receptor partial agonists for smoking cessation. Cochrane Database of Systematic Reviews 2012.
  57. Jiménez-Ruiz C, Berlin I, Hering T. Varenicline: a novel pharmacotherapy for smoking cessation. Drugs 2009;69:1319-38.
  58. FDA. Drug Safety Communication: FDA revises description of mental health side effects of the stop-smoking medicines Chantix (varenicline) and Zyban (bupropion) to reflect clinical trial findings. (2009):[6 p.].
  59. Thomas KH, Martin RM, Knipe DW, Higgins JPT, Gunnell D. Risk of neuropsychiatric adverse events associated with varenicline: systematic review and meta-analysis. BMJ : British Medical Journal 2015;350:h1109.
  60. Molero Y, Lichtenstein P, Zetterqvist J, Gumpert CH, Fazel S. Varenicline and risk of psychiatric conditions, suicidal behaviour, criminal offending, and transport accidents and offences: population based cohort study. Bmj 2015;350:h2388.
  61. Mills EJ, Thorlund K, Eapen S, Wu P, Prochaska JJ. Cardiovascular events associated with smoking cessation pharmacotherapies: a network meta-analysis. Circulation 2014;129:28-41.
  62. Kotz D, Viechtbauer W, Simpson C, van Schayck OC, West R, Sheikh A. Cardiovascular and neuropsychiatric risks of varenicline: a retrospective cohort study. Lancet Respir Med 2015;3:761-8.
  63. Tutka P, Vinnikov D, Courtney RJ, Benowitz NL. Cytisine for nicotine addiction treatment: a review of pharmacology, therapeutics and an update of clinical trial evidence for smoking cessation. Addiction 2019;114:1951-69.
  64. Courtney RJ, McRobbie H, Tutka P, Weaver NA, Petrie D, Mendelsohn CP, et al. Effect of Cytisine vs Varenicline on Smoking Cessation: A Randomized Clinical Trial. Jama 2021;326:56-64.
  65. Phusahat P, Dilokthornsakul P, Boonsawat W, Zaeoue U, Hansuri N, Tawinkan N, et al. Efficacy and Safety of Cytisine in Combination with a Community Pharmacists' Counselling for Smoking Cessation in Thailand: A Randomized Double-Blinded Placebo-Controlled Trial. Int J Environ Res Public Health 2022;19.
  66. Ofori S, Lu C, Olasupo OO, Dennis BB, Fairbairn N, Devereaux PJ, Mbuagbaw L. Cytisine for smoking cessation: A systematic review and meta-analysis. Drug Alcohol Depend 2023;251:110936.
  67. Scharfenberg G, Benndorf S, Kempe G. [Cytisine (Tabex) as a pharmaceutical aid in stopping smoking]. Dtsch Gesundheitsw 1971;26:463-5.
  68. Vinnikov DV, Brimkulov NN, Burjubaeva A. A Double-blind, Randomised, Placebo-controlled Trial of Cytisine for Smoking Cessation in Medium-dependent Workers. The Journal of Smoking Cessation 2008;3:57-62.
  69. West R, Zatonski W, Cedzynska M, Lewandowska D, Pazik J, Aveyard P, Stapleton J. Placebo-controlled trial of cytisine for smoking cessation. N Engl J Med 2011;365:1193-200.
  70. Lareb. Tabex ® (cytisine and psychiatric adverse reactions) – an update. Lareb: 2020 august. Report No.
  71. Addendumwerkgroep. Addendum Behandeling van tabaksverslaving en stoppen-met-roken ondersteuning bij zwangere vrouwen. Trimbos-Instituut: 2017.
  72. Heddema S, Erwich R, Van Oppenraaij R, Slingerland J, Been J, Croes M, al. e. Praktijkadvies gebruik nicotinevervangende middelen in de zwangerschap. Trimbos: Trimbos; 2018. p. 1-2.
  73. Claire R, Chamberlain C, Davey MA, Cooper SE, Berlin I, Leonardi-Bee J, Coleman T. Pharmacological interventions for promoting smoking cessation during pregnancy. Cochrane Database Syst Rev 2020;3:Cd010078.
  74. Taylor L, Claire R, Campbell K, Coleman-Haynes T, Leonardi-Bee J, Chamberlain C, et al. Fetal safety of nicotine replacement therapy in pregnancy: systematic review and meta-analysis. Addiction 2020;116:239-77.
  75. Vila-Farinas A, Pérez-Rios M, Montes-Martinez A, Ruano-Ravina A, Forray A, Rey-Brandariz J, et al. Effectiveness of smoking cessation interventions among pregnant women: An updated systematic review and meta-analysis. Addict Behav 2024;148:107854.
  76. Morales-Suárez-Varela M, Puig BM, Kaerlev L, Peraita-Costa I, Perales-Marín A. Safety of Nicotine Replacement Therapy during Pregnancy: A Narrative Review. International Journal of Environmental Research and Public Health 2023;20.
  77. Berlin I, Grangé G, Jacob N, Tanguy ML. Nicotine patches in pregnant smokers: randomised, placebo controlled, multicentre trial of efficacy. Bmj 2014;348:g1622.
  78. Coleman T, Cooper S, Thornton JG, Grainge MJ, Watts K, Britton J, Lewis S. A randomized trial of nicotine-replacement therapy patches in pregnancy. N Engl J Med 2012;366:808-18.
  79. Kapur B, Hackman R, Md P, Klein J, Koren G. Randomized, Double-Blind, Placebo-Controlled Trial of Nicotine Replacement Therapy in Pregnancy. Current Therapeutic Research-clinical and Experimental - CURR THER RES 2001;62:274-8.
  80. Oncken C, Dornelas E, Greene J, Sankey H, Glasmann A, Feinn R, Kranzler HR. Nicotine gum for pregnant smokers: a randomized controlled trial. Obstet Gynecol 2008;112:859-67.
  81. Oncken C, Dornelas EA, Kuo CL, Sankey HZ, Kranzler HR, Mead EL, Thurlow MSD. Randomized Trial of Nicotine Inhaler for Pregnant Smokers. Am J Obstet Gynecol MFM 2019;1:10-8.
  82. Wisborg K, Henriksen TB, Jespersen LB, Secher NJ. Nicotine patches for pregnant smokers: a randomized controlled study. Obstet Gynecol 2000;96:967-71.
  83. Gaither KH, Brunner Huber LR, Thompson ME, Huet-Hudson YM. Does the use of nicotine replacement therapy during pregnancy affect pregnancy outcomes? Matern Child Health J 2009;13:497-504.
  84. Lassen TH, Madsen M, Skovgaard LT, Strandberg-Larsen K, Olsen J, Andersen AM. Maternal use of nicotine replacement therapy during pregnancy and offspring birthweight: a study within the Danish National Birth Cohort. Paediatr Perinat Epidemiol 2010;24:272-81.
  85. Dhalwani NN, Szatkowski L, Coleman T, Fiaschi L, Tata LJ. Stillbirth Among Women Prescribed Nicotine Replacement Therapy in Pregnancy: Analysis of a Large UK Pregnancy Cohort. Nicotine Tob Res 2019;21:409-15.
  86. Strandberg-Larsen K, Tinggaard M, Nybo Andersen AM, Olsen J, Grønbaek M. Use of nicotine replacement therapy during pregnancy and stillbirth: a cohort study. Bjog 2008;115:1405-10.
  87. Morales-Suárez-Varela MM, Bille C, Christensen K, Olsen J. Smoking habits, nicotine use, and congenital malformations. Obstet Gynecol 2006;107:51-7.
Keuzekaart - Stoppen met roken
NHG-Behandelrichtlijn Stoppen met roken
NHG-werkgroep:
Damen Z, Heemstra I, Muris J, Oud M, Schep A, Statius Muller I, van Walraven A, Wind L
4 gerelateerde lacunesGerelateerd onderzoek
E-mail